Ovid Therapeutics Inc. is striving to conquer seizures and intractable brain disorders with courageous science. The Company is advancing a focused pipeline of targeted small molecule candidates to modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitation, which can cause seizures and other neuropathological symptoms. Programs Ovid seeks to develop include GV101, a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations; OV329, a GABA-aminotransferase inhibitor, for the potential treatment of treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies. In addition, the Company's ROCK2 inhibitor and KCC2 activator portfolios have the potential to treat other neurological conditions. Ovid also maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, a cholesterol 24-hydroxylase inhibitor, for Dravet and Lennox-Gastaut syndromes, which Takeda is responsible for advancing globally.
Ovid Therapeutics is striving to conquer seizures and intractable brain disorders with courageous science by advancing a focused pipeline of targeted small molecule candidates to modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitation, which can cause seizures and other neuropathological symptoms. Ovid's programs include GV101, a potent and highly selective ROCK2 inhibitor; OV329, a GABA-aminotransferase inhibitor; and OV350, a direct activator of the KCC2 transporter.